Article metrics

Original research
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

 

Online download statistics by month:

Online download statistics by month: to

AbstractFullPdf
Total000